Delcath Systems, Inc. Provides Update on Progress; Patient Enrollment in Phase III Metastatic Melanoma Trial Now at 79 Conference Call to Discuss Second Quarter Results Today at 4:30 PM ET

NEW YORK, July 27 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH - News), a medical technology company developing a minimally invasive drug delivery platform for the regional treatment of cancer metastatic to the liver, today reported on the Company’s recent progress. In addition, the Company reported its financial results for the second quarter ended June 30, 2009.